Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Central retinal vein occlusion

Retinal or vitreous hemorrhage, retinal detachment, transient or permanent visual loss central retinal vein occlusion... [Pg.1008]

Intravitreal triamcinolone injection is safe and effective for cystoid macular edema caused by uveitis, diabetic maculopathy, and central retinal vein occlusion, and for pseudophakic cystoid macular edema. Potential risks include glaucoma, cataract, retinal detachment, and endophthalmitis. Infectious endophthalmitis is extremely rare when appropriate sterile technique is practised. Seven patients developed a clinical picture simulating endophthalmitis after intravitreal injection of triamcinolone (71). The authors believed that this effect was a toxic reaction to the injected material and explained that the differential diagnosis of infectious endophthalmitis in eyes that have been injected with triamcinolone under sterile conditions includes a sterile toxic endophthalmitis that requires careful monitoring, perhaps every 8-12 hours, in order to determine whether the inflammation is worsening or improving. Resolution occurs spontaneously, and in the absence of eye pain unnecessary intervention can be avoided. [Pg.12]

Murray DC, Christopoulou D, Hero M. Combined central retinal vein occlusion and cilioretinal artery occlusion in a patient on hormone replacement therapy. Br J Ophthalmol 2000 84(5) 549-50. [Pg.194]

Williamson TH. Central retinal vein occlusion what s the story BrJ Ophthalmol 1997 81 698-704. [Pg.28]

An additional clinical use of acetazolamide is unrelated to its ocular hypotensive properties.The 500-mg acetazolamide capsule administered daily for 2 weeks may produce either a partial or a complete resolution of macular edema in patients with cystoid macular edema (CME), retinitis pigmentosa, and chronic intermediate uveitis (pars planitis). Macular edema produced by primary retinal vascular diseases (branch and central retinal vein occlusion and macular telangiectasia) did not respond to acetazolamide therapy. It is believed that acetazolamide may improve visual function if the macular edema stems from retinal pigment epithelial dysfunction. Improved macular edema in these conditions may be associated with fluid movement from the retina to the choroid. However, acetazolamide does not appear to alter macular blood flow. [Pg.161]

The beneficial outcomes of systemic bevacizumab therapy for CNV stimulated investigators to administer the drug intravitreally, using a dose that would be therapeutically equivalent to the systemic dose used in the SANA study but approximately 400-fold less overall (about 1.25 mg total dose vs. 5 mg/kg). Although initial studies had not suggested any benefit from bevacizumab, a 1.0-mg intravitreal injection of bevacizumab was administered to a patient with wet AMD poorly responsive to pegaptanib therapy and to another patient with macular edema after central retinal vein occlusion (CRVO). Both patients demonstrated complete resolution of edema by OCT at 1 week acuity improved from 20/200... [Pg.307]

Rosenfeld PJ, Fung AE, PuMafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005 36 336. [Pg.314]

Ip MS, GottUeb JL, KahanaA, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.Arch Ophthalmol 2004 122 1131. [Pg.314]

Some patients first sign of morbidity from elevated lOP can be presentation with sudden loss of vision due to a central retinal vein occlusion (CRVO). Elevated lOP is the second most common risk factor for CRVO behind systemic hypertension. [Pg.416]

Hasan S, Elbedawi M, Castro O, et al. Central retinal vein occlusion in sickle cell disease. South Med J 2004 97 202-204. [Pg.1872]

Intravitreal triamcinolone acetonide use has increased recently following case series of successful treatment of edema due to various etiologies as well as choroidal neovascularization. It has been advocated for the treatment of macular edema associated with diabetes (54), uveitis (38,39), and central retinal vein occlusion (55). In addition, it has been proposed as adjunctive treatment for proliferative diabetic retinopathy (41) and exudative AMD (43,44). [Pg.79]

Recently, macular edema associated with uveitis (29), diabetic retinopathy (30), and central retinal vein occlusion (31,32) has been treated with intravitreal injection of triamcinolone acetonide. Macular edema decreased after treatment but recurred three to six months after injection. A sustained-release steroid delivery system may be more attractive than a simple injection of triamcinolone as it could reduce or eliminate the need for multiple intravitreal injections. [Pg.180]

Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol... [Pg.191]

Figure 2 CRVO is characterized by retinal hemorrhages in all four quadrants, venular dilation, and frequent optic nerve edema. Nerve fiber layer infarcts and macular edema may be associated features with both types of retinal vascular occlusion. Abbreviation CRVO, central retinal vein occlusion. Figure 2 CRVO is characterized by retinal hemorrhages in all four quadrants, venular dilation, and frequent optic nerve edema. Nerve fiber layer infarcts and macular edema may be associated features with both types of retinal vascular occlusion. Abbreviation CRVO, central retinal vein occlusion.
Kohner et al. (42,43) published the first controlled randomized trial using streptokinase for the treatment of central retinal vein occlusion. Of 40 patients, 20 were treated with an intravenous streptokinase bolus followed by continuous infusion for 72 hours and then use of oral warfarin for six months. Twenty patients served as controls. At one-year follow-up, the treatment group had an average gain of 1.3 lines versus the control group who lost an average of 1.5 lines (p < 0.03). [Pg.309]

Plasmapheresis has been added to hemodilution as a further method to decrease viscosity and improve blood flow. Plasmapheresis has been performed in a study of five eyes with central retinal vein occlusion where all patients improved visual acuity by at least one line at final follow-up. These authors recommended use of plasmapheresis when hemodilution has failed. [Pg.312]

The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997 115 486-491. [Pg.320]

Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981 79 371-422. [Pg.320]

Pe er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998 105 412-416. [Pg.321]

Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002 240 782-783. [Pg.322]

Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003 136 419-425. [Pg.322]

Bashshur ZF, Ma luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004 122 1137-1140. [Pg.322]

Krepler K, Ergun E, Sacu S, et al.Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005 83 71-75. [Pg.322]

Costen MT, Donaldson WB, Olson JA. Acute central retinal vein occlusion successfully treated with intravenous thrombolysis. Br J Ophthalmol 1999 83 1196-1197. [Pg.322]

Kohner EM, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in the treatment of central retinal vein occlusion. Trans Ophthalmol Soc UK 1974 94 599-603. [Pg.322]

Elman MJ. Thrombolytic therapy for central retinal vein occlusion results of a pilot study. Trans Am Ophthalmol Soc 1996 94 471-504. [Pg.322]

Paques M, Vallee JN, Herbreteau D, et al. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Br J Ophthalmol 2000 84 1387-1391. [Pg.322]

Elman MJ, Raden RZ, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc 2001 99 219-221 discussion 222-223. [Pg.322]


See other pages where Central retinal vein occlusion is mentioned: [Pg.308]    [Pg.308]    [Pg.471]    [Pg.632]    [Pg.725]    [Pg.1]    [Pg.1]    [Pg.301]    [Pg.308]    [Pg.309]    [Pg.310]    [Pg.312]    [Pg.317]   
See also in sourсe #XX -- [ Pg.632 , Pg.634 ]




SEARCH



Central retinal vein occlusion nonischemic

Occlusion

Occlusion retinal vein

Retin

Retinal

Retinitis

Veins

Veins central

© 2024 chempedia.info